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Objective: To detect high-risk human papillomavirus (hrHPV) messenger-RNA (mRNA) in urine samples, compare
their concordance with cervical samples including HPV 16 & 18/45 genotyping, and to determine the utility in
detecting  CIN 2 lesions.
Methods: A cohort of 189 non-pregnant patients (age  25) was recruited in three groups: Group 1 with abnormal
pap-smears and hrHPV positivity, Group 2 with normal pap-smears and hrHPV positivity, and Group 3 with
normal pap-smears and hrHPV negativity. Urine samples were tested for hrHPV-mRNA and subsequent hrHPVmRNA genotype if positive. High-risk HPV detection and genotyping were performed using Aptima assays
which are validated for cervical HPV testing. Colposcopy results from groups 1 & 2 were analyzed.
Results: The sensitivity of urine hrHPV-mRNA detection was 31.5% while the speciﬁcity and PPV were above 95%
(96.9% & 95.1% respectively) (p < 0.001). The kappa agreement with cervical samples was fair (0.22, p ¼ 0.04).
The sensitivity and speciﬁcity of urine hrHPV-mRNA genotyping were 20.0% & 100% respectively (p < 0.001)
with 100% genotype-speciﬁc concordance. The kappa agreement with cervical samples was fair (0.25, p ¼ 0.16).
For urine hrHPV-mRNA detection of ASC-H/HSIL when grouped by age  30, the sensitivity and speciﬁcity were
45.4% & 63.9% respectively (p ¼ 0.009). For urine hrHPV-mRNA detection of  CIN 2 for all ages, the sensitivity
and speciﬁcity were 45.5% & 75.0% respectively (p ¼ 0.03).
Conclusion: Using the Aptima Assay, urine hrHPV-mRNA detection is suboptimal for cervical cancer screening but
given the high speciﬁcity, it has the potential to identify high-grade lesions ( CIN 2). Urine hrHPV-mRNA
genotyping via this modality is not beneﬁcial in triage settings of normal or abnormal cytology to determine
the need for colposcopy.

1. Introduction
A large proportion of the population is lost to cervical cancer
screening due to poor resources, cultural barriers or avoidance of a pelvic
exam. Based on 2015 CDC statistics, the rate for cervical cancer screening
in USA was 81.8% for women ages 21 to 44, much higher than developing countries where rates are as low as 19–45% [1, 2]. In order to
increase cervical cancer screening through self-sampling, alternate
sources of detecting high-risk human papillomavirus (hrHPV) have been
studied, one of which includes urine testing [3].
Most studies involving urine hrHPV detection are based on the L1 gene
that is highly prevalent in HPV infections [4, 5, 6]. It encodes for the L1
capsid protein that facilitates entry of the virus into host epithelial cells [7].
Even though added testing for hrHPV-DNA is better in detecting high-grade

lesions than cytology alone in cervical samples, it cannot distinguish between transient or persistent infections, the latter which have a higher rate
of progression to cervical cancer [8]. The overall conclusion has been that
HPV DNA-based urine testing is concordant with cervical samples (>80%)
with high sensitivity (81–100%) but low speciﬁcity (23–51%) in detecting
 cervical intraepithelial neoplasia 2 ( CIN 2) lesions [8, 9, 10, 11, 12,
13]. Recently, HPV detection in cervical samples has been performed by
targeting the E6/E7 messenger RNA (mRNA) which makes up for the
speciﬁcity lacking in HPV-DNA assays while maintaining a high sensitivity,
thereby proving its utility in population-based primary screening [4, 6].
The rationale is that cervical carcinogenesis involves the overexpression of
viral oncogenes E6/E7 in concurrence with decreased host immunity [7,
8]. Furthermore, HPV E6/E7 mRNA has been shown to correlate with
severity of cervical lesions [5].
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Pap-smear results were reported using the Bethesda system. A normal
pap-smear included results reported as “negative for intraepithelial
lesion or malignancy [NILM].” An abnormal pap-smear included results
reported as atypical squamous cells of undetermined signiﬁcance
[ASCUS], atypical squamous cells cannot exclude high-grade squamous
intraepithelial lesion [ASC-H], low-grade squamous intraepithelial lesion
[LSIL], high-grade squamous intraepithelial lesion [HSIL], and atypical
glandular cells [AGC].

The objective and primary endpoint of this study was to detect
hrHPV-mRNA in urine samples and compare their concordance
with hrHPV-mRNA in cervical samples including HPV 16 and 18/45
genotyping. The secondary endpoint was to determine the utility of
urine hrHPV-mRNA detection for high-grade histologic lesions
( CIN 2).
2. Methods
To gain a power of 80%, a sample size of 186 patients was calculated
to estimate a 95% conﬁdence interval (CI) for the sensitivity of the urine
hrHPV-mRNA test for detecting hrHPV (assuming the prevalence of HPV
in the study population is 50%).

2.2. Sample collection
All patients enrolled in the study had their pap-smear and hrHPV
testing performed via a liquid based collection media (ThinPrep, Hologic
Inc, San Diego, CA, USA). High-risk HPV testing was performed using an
HPV-mRNA assay (Aptima HPV assay, Hologic, Inc., San Diego, CA, USA)
validated and FDA approved for cervical samples, which detects qualitative E6/E7 mRNA for the following hrHPV types: 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, and 68.
After informed consent was obtained, initial stream urine was
collected in sterile containers. Within one hour of collection, 2–2.5 ml of
urine was transferred to the urine specimen transport tube (Aptima urine
specimen collection kit, Hologic, Inc., San Diego, CA, USA), stored at 2 4  C and processed within 30 days of collection. Concurrent cervical
samples were not collected.

2.1. Study population
Inclusion criteria entailed patients  age 25 who had a pap-smear
with concurrent hrHPV testing performed (with or without hrHPV 16
and hrHPV 18/45 genotyping) within the past 360 days. Exclusion
criteria entailed patients who were pregnant or had a history of HPV
vaccine administration.
Between November 2016 and February 2018, 192 patients who
presented for their scheduled visit at Staten Island University Hospital
(SIUH), NY, were recruited. Of these patients, 189 met the inclusion
criteria.
The study design incorporated three groups of women: Group 1 with
abnormal pap-smears and hrHPV positivity, Group 2 with normal papsmears and hrHPV positivity, and Group 3 with normal pap-smears and
hrHPV negativity (Figure 1).

2.3. HPV testing
Processing of urine specimens was performed using a transcriptionmediated ampliﬁcation system (Panther Hologic System, Hologic, Inc.,

Total Cohort
N = 189

Group 1

Group 2

Group 3

Abnormal pap, hrHPV POSITIVE
N = 62 (33%)

Normal pap, hrHPV POSITIVE
N = 62 (33%)

Normal pap, hrHPV negave
N = 65 (34%)

Urine hrHPV mRNA POSITIVE
N = 23 (37%)

Urine hrHPV mRNA POSITIVE
N = 16 (26%)

Urine hrHPV mRNA POSITIVE
N = 2 (3%)

Urine mRNA genotyping:
hrHPV 16: N=5 (22%)

Urine mRNA genotyping:
hrHPV 16: N=1 (6%)

hrHPV 18/45: N=1 (4%)

Indeterminate: N=2 (13%)

Urine mRNA genotyping:
None detected

hrHPV: high-risk human papillomavirus
mRNA: messenger RNA
RNA: ribonucleic acid
Figure 1. Study design and results. hrHPV: high-risk human papillomavirus, mRNA: messenger RNA, RNA: ribonucleic acid.
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positive for urine hrHPV. None of the patients in this group tested positive on urine genotyping. The median time from pap-smear collection to
urine collection was 97 days.
The cohort characteristics are listed in Table 1. The statistically signiﬁcant differences among the characteristics were age (grouped as <30,
 30–49,  50, p ¼ 0.006) and race (grouped as Hispanic and nonHispanic, p ¼ 0.004).
Within the total cohort of 189 patients, when compared to cervical
samples, the sensitivity of urine hrHPV-mRNA detection was 31.5% and
speciﬁcity was 96.9%. The positive predictive value (PPV) was 95.1%
and negative predictive value (NPV) was 42.6%. McNemar's comparison
was statistically signiﬁcant at p < 0.001. The overall percent agreement
(OPA) was 54.0% and positive percent agreement (PPA) was 31.5%.
Refer to Table 2. The Cohen's kappa agreement was fair at 0.22
(0.10–0.34 95% CI, p ¼ 0.04).
Within Groups 1 and 2, 39 patients had positive urine hrHPV samples
of which 7 (7/39: 18%) tested positive for either hrHPV 16 or hrHPV 18/
45. Concurrent cervical hrHPV genotype information was available for
only 4 out of the 7 patients. The genotype–speciﬁc concordance for HPV
16 and 18/45 was 100% between the urine and cervical samples.
In Groups 1 and 2, 57 patients had genotyping done on both cervical
and urine samples. The sensitivity of urine hrHPV genotype detection
was 20.0% and speciﬁcity was 100%. The PPV was 100% and NPV was
69.8%. McNemar's comparison was statistically signiﬁcant at p < 0.001.
The OPA was 71.9% and PPA was 20.0%. Refer to Table 2. The Cohen's
kappa agreement was fair at 0.25 (0–0.56 95% CI, p ¼ 0.16).
A sub-analysis was performed for age  30. Comparison was made for
urine hrHPV-mRNA detection of high-grade cytology (ASC-H/HSIL)
versus low-grade cytology (ASCUS/LSIL) in Group 1. When grouped by
age  30, statistical signiﬁcance was reached with sensitivity of 45.4%
and speciﬁcity of 63.9%. This translated to a NPV of 79.3% (p ¼ 0.009).
Refer to Table 3. A higher proportion of patients  age 30 with ASC-H/
HSIL had positive urine hrHPV samples (5/11: 46%) than patients with
ASCUS/LSIL (13/36: 36%) (Figure 2).
Of the 124 patients in Groups 1 and 2, 11 patients did not have colposcopy biopsies performed based on physician judgment. The results of

San Diego, CA, USA). Urine samples were tested using the same Aptima
HPV assay as was used for cervical samples. The Aptima HPV assay involves three main steps involving HPV-mRNA target capture,
transcription-based nucleic acid ampliﬁcation of the target molecules
and their subsequent detection via hybridization with chemiluminescent
labels.
Urine samples which were positive for hrHPV-mRNA further underwent hrHPV genotyping using an HPV-mRNA 16 and 18/45 genotype
assay (Aptima HPV 16, 18/45 Genotype Assay, Hologic, Inc., San Diego,
CA, USA) validated and FDA approved for cervical samples, which detects E6/E7 HPV-mRNA.
Final assay results were interpreted based on analyte signal-to-cut off
(S/CO) ratio incorporating pre-determined relative light unit (RLU)
values used for cervical samples. Colposcopy results of patients from
Groups 1 and 2 were collected.
2.4. Statistical analysis
Comparison of categorical values was performed using Pearson and
chi-square tests. Comparison of urine and cervical hrHPV test results was
performed using McNemar's test. All comparisons were two-sided and pvalues for 0.05 were considered statistically signiﬁcant. Percent
agreement adjusted for chance agreement was calculated using the
Cohen's kappa coefﬁcient. Statistical analyses were performed using SPSS
software (IBM Corp, 2012, Version 21.0, Armonk, NY, USA).
3. Results
The total cohort involved 189 patients (Figure 1). Group 1 included
62 (62/189: 33%) patients of which 23 (23/62: 37%) tested positive for
urine hrHPV. Of those 23 patients, 5 (5/23: 22%) tested positive for
hrHPV 16 and 1 (1/23: 4%) tested positive for hrHPV 18/45. Group 2
included 62 (62/189: 33%) patients of which 16 (16/62: 26%) tested
positive for urine hrHPV. Of those 16 patients, 1 (1/16: 6%) tested
positive for hrHPV 16 and 2 (2/16: 13%) tested as indeterminate. Group
3 included 65 (65/189: 34%) patients of which 2 (2/65: 3%) tested

Table 1. Cohort characteristics.
Total
N
N

%

Group 1 ¼ Abnormal pap, hrHPV POSITIVE

Group 2 ¼ Normal pap, hrHPV POSITIVE

Group 3 ¼ Normal pap, hrHPV negative

N

%

N

%

N

%

189

62

32.8%

62

32.8%

65

34.4%

41

36

Age (years)
Median

42

45

Age Groups (years) **
<30

24

12.7%

15

24.2%

7

12.3%

2

3.1%

30-49

108

57.1%

34

63.0%

35

61.4%

39

60.0%

50

57

30.1%

13

24.0%

20

35.1%

24

36.9%

Hispanic

92

48.7%

29

53.7%

40

70.2%

23

35.4%

Non-Hispanic

97

51.3%

33

61.1%

22

38.6%

42

64.6%

0-1

47

24.9%

22

40.7%

8

14.0%

17

26.2%

2-4

117

61.9%

34

63.0%

42

73.7%

41

63.1%

5

15

7.9%

3

5.6%

6

10.5%

6

9.2%

Yes

30

15.9%

12

22.2%

10

17.5%

8

12.3%

No

159

84.1%

50

92.6%

52

91.2%

57

87.7%

Race**

Parity (NS)

Smoking

(NS)

History of past or present sexually transmitted diseases (STD) (NS)
Yes

28

14.8%

14

26.0%

9

15.8%

5

7.7%

No

161

85.2%

48

89.0%

53

93.0%

60

92.3%

hrHPV: high-risk human papillomavirus; (NS): Not Signiﬁcant.
**p < 0.01.
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Table 2. Urine hrHPV and hrHPV genotype detection compared to cervical samples.
Groups compared

Urine samples Cervical samples
hrHPV positive

1, 2, 3 Urine hrHPV detection
(compared to cervical
hrHPV detection)

Prevalence % Sensitivity % Speciﬁcity % PPV %
(95% CI)
(95% CI)
(95% CI)
(95% CI)

hrHPV negative

hrHPV positive 39

2

hrHPV negative 85

63

NPV %
(95% CI)

McNemar Overall
Positive
p-value percent
percent
agreement agreement

65.6
(58.3–72.2)

31.5
(23.6–40.5)

96.9
(88.3–99.5)

95.1
42.6
<0.001
(82.2–99.2) (34.6–51.0)

54.0%

31.5%

35.1
(23.2–48.9)

20.0
(6.6–44.3)

100
100
69.8
<0.001
(88.3–100.0) (39.6–100.0) (55.5–81.3)

71.9%

20.0%

hrHPV 16 or 18/45 positive hrHPV 16 or 18/45 negative
1,2 # Urine hrHPV genotyping hrHPV 16 or
4
(compared to cervical
18/45 positive
hrHPV genotyping)
hrHPV 16 or
16
18/45 negative

0
37

# (57 patients had concurrent genotyping at time of pap smear collection); hrHPV: high-risk human papillomavirus; PPV: Positive predictive value; NPV: Negative
predictive value; CI: Conﬁdence interval.

Table 3. Urine hrHPV detection by cervical cytology and histology.
Groups compared

Age

Urine samples

Cervical samples
ASC-H/HSIL

ASCUS/LSIL

1

All (NS)

hrHPV positive

5

18

hrHPV negative

9

30

1,2 #

Urine hrHPV detection (for high
grade cytology (ASC-H/HSIL) versus
low grade cytology (ASCUS/LSIL))

Urine hrHPV detection
(for ≥ CIN 2 versus ≤ CIN 1)

 30 **

All *
≥ 30

(NS)

hrHPV positive

5

13

hrHPV negative

6

23

≥ CIN 2

≤ CIN 1

hrHPV positive

15

20

hrHPV negative

18

60

hrHPV positive

12

16

hrHPV negative

15

46

Prevalence
% (95% CI)

Sensitivity
% (95% CI)

Speciﬁcity
% (95% CI)

PPV
% (95% CI)

NPV
% (95% CI)

22.6
(12.3–35.3)

35.7
(14.0–34.4)

62.5
(47.3–75.7)

21.7
(8.3–44.2)

76.9
(60.3–88.3)

23.4
(12.8–38.4)

45.4
(18.1–75.4)

63.9
(46.2–78.7)

27.8
(10.7–53.6)

79.3
(59.7–91.3)

29.2
(21.2–38.6)

45.5
(28.5–63.4)

75.0
(63.8–83.7)

42.8
(26.7–60.5)

76.9
(65.8–85.4)

30.3
(21.2–41.1)

44.4
(26.0–64.3)

74.1
(61.2–84.1)

42.8
(25.0–62.6)

75.4
(62.4–85.1)

# (11 patients did not have colposcopies); hrHPV: high-risk human papillomavirus; PPV: Positive predictive value; NPV: Negative predictive value; CI: Conﬁdence
interval; (NS): Not Signiﬁcant; CIN: Cervical intra intraepithelial neoplasia; ASC-H: Atypical squamous cells, cannot rule out HSIL; HSIL: High-grade squamous
intraepithelial lesion; ASCUS: Atypical squamous cells of undetermined signiﬁcance; LSIL: Low-grade squamous intraepithelial lesion.
**p < 0.01.
*p < 0.05.

infection with higher risk of progression, thereby used to improve
sensitivity of CIN 3 detection versus cytology alone [15, 16]. In this
study, a high speciﬁcity of 63.9% of urine hrHPV-mRNA detection in
patients  age 30 who had high-grade cytology (ASC-H/HSIL) was noted
in Group 1 with a sample size of 47 patients. This is comparable to the
speciﬁcity determined by Ascuitto et al of 61.9% of urine hrHPV-mRNA
detection of high-grade lesions (HSIL/AIS/cancer) [3]. The speciﬁcity in
this study is higher than the 41% speciﬁcity that was observed in
biopsy-conﬁrmed  HSIL in cervical samples using the Aptima HPV
Assay [17]. Although the ultimate end-point is to detect high-grade
histology (CIN 2/CIN 3/carcinoma), there is a beneﬁt in detecting
high-grade cytology which generally correlates to high-grade cervical
dysplasia. A larger sample size would be necessary to enhance precision
of the statistically signiﬁcant results obtained.
In Groups 1 and 2, there was a high speciﬁcity of 75.0% for patients
with  CIN 2 histology. This is equivalent or higher than the speciﬁcities
of detection of  CIN 2 in several studies (40–75%) using the same
hrHPV-mRNA assay on cervical samples in a referral population [18, 19,
20, 21, 22]. Iftner et al, however, was able to demonstrate a signiﬁcantly
high speciﬁcity of 96.1% for  CIN 3 using the Aptima HPV assay on
cervical samples in a screening population [23]. The increased speciﬁcity
in urine samples can potentially be used to identify high-grade lesions (
CIN 2). A high percentage of patients (83%) with  CIN 2 histology had
positive urine hrHPV results compared to patients with  CIN 1 (33%),
which further substantiates the potential for this mode of urine hrHPV
detection for triage of abnormal cytology to pursue colposcopy in positive samples.
For HPV 16 or HPV 18/45 genotyping, the OPA was 71.9% with a low
PPA of 20.0%. Nevertheless, the genotype-speciﬁc concordance with

113 patients who underwent colposcopies were grouped into two categories:  CIN 1 (including benign results) and  CIN 2 (CIN 2, CIN 3).
None of the patients were diagnosed with carcinoma.
When the two categories were compared, the sensitivity for detecting
urine hrHPV-mRNA for patients of all ages with  CIN 2 was 45.5% and
speciﬁcity was 75.0%. The PPV was 42.8% and NPV was 76.9%. All results were statistically signiﬁcant (p ¼ 0.03). Refer to Table 3. A higher
proportion of patients of all ages with  CIN2 had positive urine hrHPVmRNA samples (15/18: 83%) than patients with  CIN 1 (20/60: 33%)
(Figure 3).
4. Discussion
In this study, the overall sensitivity of urine hrHPV-mRNA detection is
low (31.5%), however the speciﬁcity and PPV are above 95% (96.9% and
95.1% respectively). Given the fair agreement between cervical and
urine samples (k ¼ 0.22) and low OPA of 54%, this modality of urine
hrHPV-mRNA testing is not appropriate for primary cervical cancer
screening. Similar results were noted by Ascuitto et al who demonstrated
a 48.1% sensitivity and 82.8% speciﬁcity of urine hrHPV-mRNA detection using the Aptima HPV assay in 209 patients [3]. The decreased OPA
of urine hrHPV-mRNA detection can be attributed to the use of assay
cut-offs for positive results based on cervical samples, which in general
yield higher concentrations of infected cells. The addition of Proteinase K
to increase HPV-RNA extraction with the Aptima HPV assay has been
shown to increase agreement rates between urine and cervical
hrHPV-mRNA detection but was not used in this study [14].
A sub-analysis was performed on patients  age 30 because it is
known that HPV detection in this age group represents a more persistent
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40

Urine hrHPV posive

36

Cervical hrHPV posive

35

No. of samples

30

25

20

13

15

11
36%

10

5
5

46%
0

ASC-H / HSIL

ASCUS / LSIL

Cervical Cytology
hrHPV: high-risk human papillomavirus
HSIL: High-grade squamous intraepithelial lesion
ASC-H: Atypical squamous cells, cannot rule out HSIL
LSIL: Low-grade squamous intraepithelial lesion
ASCUS: Atypical squamous cells of undetermined signiﬁcance

Figure 2. Proportion of urine hrHPV mRNA positive samples in Group 1 separated by cytology for age 30. hrHPV: high-risk human papillomavirus, HSIL: High-grade
squamous intraepithelial lesion, ASC-H: Atypical squamous cells, cannot rule out HSIL, LSIL: Low-grade squamous intraepithelial lesion, ASCUS: Atypical squamous
cells of undetermined signiﬁcance.

sensitivity of 89% [13]. Future studies are required to assess the different
methods of urine collection and voiding times to determine the highest
yield of infected cells for detection and genotyping.

cervical samples was 100% and the speciﬁcity for urine hrHPV-mRNA
genotyping was 100%. As demonstrated by the CLEAR trial using the
Aptima HPV genotype assay on cervical samples, women who tested
positive for HPV 16 or HPV 18/45 had a 29.1% absolute risk of  CIN 2
and 16.2% absolute risk of CIN 3/AIS [24]. The low PPA between urine
and cervical samples in this study deters the use of urine HPV-mRNA
genotype testing in a triage setting for normal or abnormal cytology to
determine the need for colposcopy.
This was not a longitudinal study and disease progression was not
studied, which is a limitation. A study involving low-risk population with
11220 women showed an overall cumulative rate of 19.7% over 72
months of  CIN 3 in patients who were mRNA-HPV positive versus
0.62% in patients who were mRNA-HPV negative in cervical samples
[25]. Furthermore, Bruno et al demonstrated that 97.1% of patients who
were HPV-DNA positive but E6/E7 mRNA negative and with ASCUS/LSIL
cytology at baseline did not progress during a follow-up period of 3 years
[26]. In women who were E6/E7 mRNA positive, 45.2% in the ASCUS
group and 12.9% in the LSIL group developed  CIN 2 during the 3 years
of follow-up [26]. Long-term follow-up will be required to ascertain the
signiﬁcance of positive urine hrHPV-mRNA detection in the setting of
disease course.
As to hrHPV-DNA studied in urine samples, there is no consensus on
urine collection modes or HPV-DNA extraction methods from urine
samples [13, 27, 28]. Some studies have found higher sensitivity and
speciﬁcity for HPV-DNA detected in ﬁrst-void samples based on the
theory that initial-ﬂow urine collects most of the debris [28, 29]. In 30
patients with  CIN 2 or worse, Senkomago et al found no difference on
hrHPV-DNA detection for ﬁrst-void, initial-stream and mid-stream urine
samples for unfractionated and pellet fractions with an overall high

5. Conclusion
The detection of hrHPV-mRNA in urine samples using the Aptima
HPV assay is suboptimal for cervical cancer screening. However, due to
the comparably high speciﬁcities to cervical samples as determined by
numerous studies, urine hrHPV-mRNA detection may have a utility in
identifying high-grade lesions ( CIN 2) if substantiated by future studies
[18, 19, 20, 21, 22]. This would potentially lower the number of colposcopies and accommodate increased testing frequency during surveillance. It may also be used in triage of abnormal cytology with respect
to concurrent colposcopies, thereby being cost effective.
This is the ﬁrst known study to test for urine hrHPV-mRNA genotype
using the Aptima HPV 16 and 18/45 genotype assay. The low PPA with
cervical samples discourages its use in triage settings, especially for lowgrade lesions, irrespective of a high speciﬁcity.
The rationale for the study design was to include equal number of
patients within each test group for a uniform statistical comparison. It
accommodates a sample size to attain certain signiﬁcant results which
may be used as basis for future large population-based studies.
6. Limitations
First-void urine samples were not used which theoretically have a
higher concentration of infected cells. Urine collection at time of visit was
done to mimic the clinical setting as close to reality as possible where
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Urine hrHPV posive
Cervical hrHPV posive

60

60

No. of Samples

50

40

30

20

18

20

15

33%

83%
10

0

≥ CIN 2

Cervical Histology

≤ CIN 1

hrHPV: high-risk human papillomavirus
CIN: Cervical intraepithelial neoplasia

Figure 3. Proportion of urine hrHPV mRNA positive samples in Groups 1 and 2 separated by histology. hrHPV: high-risk human papillomavirus, CIN: Cervical
intraepithelial neoplasia.

obtaining ﬁrst-void samples would unlikely procure a high compliance
rate.
Additionally, the lack of paired cervical and urine samples is a
weakness. The median time between pap-smear and urine collection was
97 days and it is well-known that cytology and HPV status are prone to
change over time. In these cases, regression of disease was not accounted
for. Therefore, there is a deﬁciency in clinical accuracy due to nonsimultaneous comparison of urine and cervical samples using the same
HPV assay under standardized conditions. The VALHUDES protocol was
recently undertaken in 2018 to target this deﬁciency on ﬁrst-void urine
samples [30]. Future studies will need to be undertaken with emphasis
on paired cervical and urine samples to nullify regression of disease as a
confounding factor.
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